Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer

NCT05500508 is registered in ClinicalTrials.gov with Aminex Therapeutics, Inc. as lead sponsor.

NCT NCT05500508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05500508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
Lead sponsor
Aminex Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
November 29, 2022
Completion date
December 12, 2024
Enrollment
15 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, breast cancer, cancer, cervical cancer, colorectal cancer, diffuse midline glioma, h3 k27m-mutant, dipg brain tumor, endometrial cancer, esophageal cancer, gastric cancer, glioma, malignant, head and neck cancer, melanoma, mesothelioma peritoneum, mesotheliomas pleural, nsclc, ovary cancer, papillary thyroid cancer, solid carcinoma, solid tumor